ArticleThe American journal of pathology2026
MYC Is Functionally Required in Both Normal and Neoplastic Meibomian Glands.
Article in The American journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Despite the clinical importance of the meibomian gland (MG), the mechanisms controlling its proliferation and differentiation remain unclear. Ocular adnexal sebaceous carcinoma (SebCA), an aggressive malignancy that most often arises from the MG, lacks well-defined oncogenic drivers, but high MYC expression has been demonstrated in both tumors and primary human cell lines. This study evaluated the ongoing dependence of MYC in the MG. MYC-modulated murine MGs were evaluated using histopathology, morphometry, immunohistochemistry, and quantitative PCR. Viability, differentiation, and proliferation were evaluated in vitro, clonogenic potential was assessed by quantifying anchorage-dependent colony formation, and MYC expression was determined using enzyme-linked immunosorbent assay and quantitative PCR. MYC-inhibited murine MGs exhibited significantly reduced cytoplasmic volume with diminished proliferation and increased apoptosis with altered lipid droplet formation relative to contralateral control eyelids. SebCA viability and clonogenicity were significantly impaired by MYC inhibition, and proliferation was significantly reduced in all cells following incubation with MYCMI6. MYCMI6 also showed the most prominent suppression of canonical MYC transcriptional targets of the three MYC inhibitors used. MYC concentration was significantly lower in MYCi361- and 10074-G5-treated cells relative to vehicle control, and relative MYC expression was significantly up-regulated in 10074-G5-treated SebCA01 cells. MYC stability, MYC transcriptional activity, and the MYC:MAX heterodimer may represent critical regulators of proliferation and differentiation in the MG, with dysregulation contributing to oncogenic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.